Member Info for luvelyjubley

The longer the delay and any resistance to the outcome by the government is an own goal, why any investors would want to support any business venture in their country.

The longer this drags on makes it look like the arbitration is being guided by political influence and not being impartial.

The shenanigans going on in the euro zone after the Hungary election may be having a spin off on this process.

The quicker this gets resolved the better, there have been a few financial reporters watching what is going on here.

I wonder if the arbitration was waiting to see what the outcome of the court judgement would be before finalising details?

Hopefully the decks are cleared now and they can sort out any loose ends.

I was thinking the same re the valuation of the gas reserves and wondered if they would be taken into account.

Hopefully not long to wait now, I believe the decision by this arbitration is final and there is no appeal or means to drag it out.

If any large pharma was interested in a tyk2 they may be tempted with a carrot of some substantial data from the initial trial with the results of the bio markers.

It has been over a year now since the trial was completed and yet the report has yet to be published. How can the "world see what we have " if it is stuffed in Mr Parkers bottom drawer.

I thought it was the legal responsibility of the Nomad to ensure shareholders interests were looked after? Why is this data being with held. I am still waiting for the announcement "Professor John Reader'

The RNS states "The Company has recently acquired the license for SRA737" you are having a laugh you have had it for over 12 months and still assessing what to do with it, Its like the "Very Soon" statement that was mentioned about 4 months ago.

We are now just waiting for the announcement of the award of the title "PROFFESSOR John Reader" for his outstanding life's work in drug development which has recently been scrutinised by his peers (probably some of the HNWI's) and is being published in the 2026 Xmas edition of the Beano. (very soon).

He will of course be nominated for a knighthood and might even challenge Donald Trump for a Nobel prize for science.

Our Donald is playing havoc with the price of gas in europe with his world tantrum, only hope when they calculate the value of the asset they keep it updated

I am thinking similar, I check every day hoping for a nice surprise. If they had the draft prepared weeks ago I would have thought it would not be long before final report produced and signed off.

I only hope that it is enough to be able to walk away from the country and leave the gas field for them to develop themselves.

Nearly there yet? Should not be long before judgement day.

The outcome could have major implications for the investment of small international companies in the region.

When the arbitration is sorted who owns the asset ie the gas field, is it ours to sell?

Nice article and hopefully BMS might want to retain their crown and add our products to their portfolio.

If Mr Parker would kindly forward them a copy of the phase 1 trial data (which was to be published Very Soon) together with a note saying we have commenced tox trials , please give me a ring to discuss how we may be of service.

Mr Parker stated the initial trial data would be peer reviewed and published in a journal 'very soon" as this statement was made about 3 months ago is this not tantamount to misleading the market (and shareholders) ?

I personally feel the data is being withheld as the BOD are frightened of a low ball offer, the longer this is allowed to drift the greater the distance the BOD are putting between themselves and us.

Mr Parker in the absence of any news be a good chap and get one of the directors to buy some shares or one of your hnwi pals to throw an odd million change into our pot.

As they had completed the draft document a few weeks ago hopefully not long to wait for final determination.

The gas price must be at a high price (value of the gas field) with the war in Ukraine, I just hope the outcome is favourable and proportionate to the value of the asset and the time (and money) wasted by political games.

What happened to the "Very Soon" peer review and publication in a journal? No mention in chairman's corner also I thought from the AGM that 737 and 1802 were to be packaged up and put on American Market looking for a strategic partner.

The article is a bit of window dressing to dampen down the frustration being vented by the shareholders as to the lack of progress in getting a commercial deal on any of our products.

The final paragraph about the BOD is that a reality check in that they might be lacking in experience to get a deal done and need to strengthen the BOD with a new striker?

Are they playing for time and keeping all the products together so as to get the tox study done and sell the whole lot together.

Hi Steve

The radio silence from the BOD only adds to them distancing themselves and if a low ball offer from a hostile takeover comes in , then all of a sudden they need the support of the shareholders to reject the offer (as they deem the company worth more).

They might get a surprise the amount of shareholders who accept just to get out and see the back of them, here's hoping someone snaps us up and drives the development of the drugs.

Article on endpoints "moderna CEO says the deals team is reviewing a number of opportunities" I hope Mr Parker has been knocking on his door .

Also Merck looking at patent defense for Keytruda,.

As the patents run out all the big boys are looking to snap up the smaller companies to maintain their income.

It's all to play for, we should be getting the initial 1801 trial results published "VERY SOON", the AI study and news of start of tox study. Or is the trial results being withheld as the BOD are frightened of a low ball offer.

The drugs have a value now but carry more risk, but if any pharma liked what they saw and was prepared to carry an element of risk they could have 737, 1801, 1802 and the new drug which crossed the blood brain barrier together with the SKIL platform and an FLT.

Any offers over £2 a share and they can have all my shares, come on guys the January sales are nearly over.

Jemperli a checkpoint inhibitor just announced a 100% success rate in a trial for rectal cancer, owned by GSK.

Isn't it strange that gsk who bought siera, stalled the development of 737, then the following year and unknown American company stalled it for another year (siera are American owner by gsk ) then our BOD get control and stall it for another year.

I have just ran a request on chat gpt to produce a list of all of the trials that 737 has been used in and it is very interesting.

Why this has not been commercialised does not add up and needs investigating by UK government, I might just ask local MP how to go about process.

Here is a bit of reading for the weekend to help keep the spirits up, fingers crossed for our turn next (VERY SOON)

https://www.cnbc.com/amp/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html

I think a few investor publications are watching for the outcome of the arbitration ruling, my understanding is their ruling is final and there is no appeals, if they decide a guilty party has to pay again I beleive there is no option for refusal. An amount and a date by which it must be paid is set.

The outcome will have implications for future investments in the country and even other European countries so watch this space, fingers crossed it is very favourable in light of the amount of time this has dragged on and also now the high value of the gas reserves.

Another nice article published by endpoints re successful two phase 3 trials of another tyk2 drug, envudeucitinib which they are putting forward for FDA approval for psoriasis.

The more tyk2 drugs that make the grade de risks the general drug classification and if the end global market is of a decent size then adds value to our products.

How many tyk2 drugs that are in development are in the hands of small pharmas just waiting to be snapped up.

Come on Mr Parker let's get our 1801 and 1802 in the shop window it's January sales time and loads of patents expiring soon which big pharma need to replace.